Restless legs syndrome—current therapies and management of augmentation

被引:0
|
作者
Claudia Trenkwalder
Juliane Winkelmann
Yuichi Inoue
Walter Paulus
机构
[1] Paracelsus Elena Klinik,Department of Neurosurgery
[2] Centre of Parkinsonism and Movement Disorders,Department of Clinical Neurophysiology
[3] Kassel,Department of Neurology and Neurological Sciences and Centre for Sleep Sciences and Medicine
[4] University Medical Centre Göttingen,Department of Somnology
[5] University Medical Centre Göttingen,undefined
[6] Stanford University,undefined
[7] Neurologische Klinik und Poliklinik,undefined
[8] Klinikum rechts der Isar,undefined
[9] Technische Universität München,undefined
[10] Japan Somnology Center,undefined
[11] Neuropsychiatric Research Institute,undefined
[12] Tokyo Medical University,undefined
来源
Nature Reviews Neurology | 2015年 / 11卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Treatment of restless legs syndrome (RLS) usually involves dopamine agonists, which are approved for treatment of RLS in most countries; α-2-δ ligands, such as gabapentin enacarbil and pregabalin, are also effectiveIn patients with RLS who have low levels of ferritin, iron supplementation should be the first-line therapyFor patients with severe RLS, opioids such as oxycodone–naloxone are an option as second-line therapy where they are approvedAugmentation is a major complication of long-term RLS therapy with dopaminergic agents, and is related to high doses of dopaminergicsInternational treatment guidelines recommend weighing the benefits against the risks for each drug class when initiating treatmentCombined treatment approaches are used on the basis of expert opinions, and are currently not evidenced-based
引用
收藏
页码:434 / 445
页数:11
相关论文
共 50 条
  • [21] Handling the problem of augmentation in restless legs syndrome (RLS)
    Stiasny, K
    EUROPEAN JOURNAL OF NEUROLOGY, 2001, 8 : 12 - 15
  • [22] Restless legs syndrome and transdermal fentanyle: a case of augmentation
    Santos-Canelles, H.
    EUROPEAN JOURNAL OF NEUROLOGY, 2015, 22 : 219 - 219
  • [23] Augmentation in the treatment of restless legs syndrome with transdermal rotigotine
    Benes, Heike
    Garcia-Borreguero, Diego
    Ferini-Strambi, Luigi
    Schollmayer, Erwin
    Fichtner, Andreas
    Kohnen, Ralf
    SLEEP MEDICINE, 2012, 13 (06) : 589 - 597
  • [24] Factors associated with augmentation in patients with restless legs syndrome
    Heim, Beatrice
    Ellmerer, Philipp
    Stefani, Ambra
    Bergmann, Melanie
    Brandauer, Elisabeth
    Seppi, Klaus
    Hoegl, Birgit
    Djamshidian, Atbin
    EUROPEAN JOURNAL OF NEUROLOGY, 2022, 29 (04) : 1227 - 1231
  • [25] Augmentation in restless legs syndrome is associated with low ferritin
    Trenkwalder, Claudia
    Hoegl, Birgit
    Benes, Heike
    Kohnen, Ralf
    SLEEP MEDICINE, 2008, 9 (05) : 572 - 574
  • [26] Current and emerging pharmaceutical strategies for the treatment and management of restless legs syndrome
    Burini, Alessandra
    Pellitteri, Gaia
    Merlino, Giovanni
    Nilo, Annacarmen
    Tereshko, Yan
    Dolso, Pierluigi
    Gigli, Gian Luigi
    Valente, Mariarosaria
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2024, 24 (10) : 997 - 1009
  • [27] An algorithm for the management of restless legs syndrome
    Silber, MH
    Ehrenberg, BL
    Allen, RP
    Buchfuhrer, MJ
    Earley, CJ
    Hening, WA
    Rye, DB
    MAYO CLINIC PROCEEDINGS, 2004, 79 (07) : 916 - 922
  • [28] Restless legs syndrome: diagnosis and management
    Tan, E. K.
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2009, 285 : S31 - S31
  • [29] Dopaminergic Augmentation in Restless Legs Syndrome/Willis-Ekbom Disease: Identification and Management
    Garcia-Borreguero, Diego
    SLEEP MEDICINE CLINICS, 2015, 10 (03) : 287 - +
  • [30] Advancing synthetic therapies for the treatment of restless legs syndrome
    de Biase, Stefano
    Pellitteri, Gaia
    Gigli, Gian Luigi
    Valente, Mariarosaria
    EXPERT OPINION ON PHARMACOTHERAPY, 2019, 20 (16) : 1971 - 1980